Advanced Medical Solutions vs Neogen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Advanced Medical Solutions Group plc (AMS.LSE)

Q3 202615 Jul – 13 Aug 2026

▲1

AMS shareholders back H.B. Fuller's cash takeover; deal on track

Shareholders approve H.B. Fuller takeover AMS shareholders voted in favour of H.B. Fuller's recommended cash buyout at meetings on 12 August. That clears a major hurdle, making the deal more likely to complete by year-end and anchoring the share price near the offered terms.
This is the single biggest new event and the main force now setting AMS's price.
Octopus keeps trimming its stake Octopus Investments disclosed its holding fell from 8.66% to 8.28% to 8.07% across July, selling shares each time. The stake is large, but the steady selling suggests it is reducing exposure rather than betting on a higher price.
Shows a major holder's behaviour, a real counterweight to deal optimism.
Broker Investec's routine share dealings Investec, AMS's joint broker, repeatedly bought and sold AMS shares in near-equal amounts around 280p. This is normal market-making tied to its advisory role, not a signal about AMS's health, so it adds little to the bigger picture.
Explains the other recurring disclosure and why it is not a real driver.

July 202615 Jul – 13 Aug 2026

▲1

AMS shareholders back H.B. Fuller's cash takeover; deal on track

Shareholders approve H.B. Fuller takeover AMS shareholders voted in favour of H.B. Fuller's recommended cash buyout at meetings on 12 August. That clears a major hurdle, making the deal more likely to complete by year-end and anchoring the share price near the offered terms.
This is the single biggest new event and the main force now setting AMS's price.
Octopus keeps trimming its stake Octopus Investments disclosed its holding fell from 8.66% to 8.28% to 8.07% across July, selling shares each time. The stake is large, but the steady selling suggests it is reducing exposure rather than betting on a higher price.
Shows a major holder's behaviour, a real counterweight to deal optimism.
Broker Investec's routine share dealings Investec, AMS's joint broker, repeatedly bought and sold AMS shares in near-equal amounts around 280p. This is normal market-making tied to its advisory role, not a signal about AMS's health, so it adds little to the bigger picture.
Explains the other recurring disclosure and why it is not a real driver.

Latest15 Jul – 13 Aug 2026

▲1

AMS shareholders back H.B. Fuller's cash takeover; deal on track

Shareholders approve H.B. Fuller takeover AMS shareholders voted in favour of H.B. Fuller's recommended cash buyout at meetings on 12 August. That clears a major hurdle, making the deal more likely to complete by year-end and anchoring the share price near the offered terms.
This is the single biggest new event and the main force now setting AMS's price.
Octopus keeps trimming its stake Octopus Investments disclosed its holding fell from 8.66% to 8.28% to 8.07% across July, selling shares each time. The stake is large, but the steady selling suggests it is reducing exposure rather than betting on a higher price.
Shows a major holder's behaviour, a real counterweight to deal optimism.
Broker Investec's routine share dealings Investec, AMS's joint broker, repeatedly bought and sold AMS shares in near-equal amounts around 280p. This is normal market-making tied to its advisory role, not a signal about AMS's health, so it adds little to the bigger picture.
Explains the other recurring disclosure and why it is not a real driver.

Neogen Corporation (NEOG)

Q3 202624 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

August 202624 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

Latest24 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.